Skip to main content

Main menu

  • Home
  • Content
    • Current
      • JNMT Supplement
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine Technology
  • SNMMI
    • JNMT
    • JNM
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine Technology

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • Continuing Education
    • JNMT Podcast
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNMT
    • Information for Authors
    • Assignment of Copyright
    • AQARA Requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Watch or Listen to JNMT Podcast
  • Visit SNMMI on Facebook
  • Join SNMMI on LinkedIn
  • Follow SNMMI on Twitter
  • Subscribe to JNMT RSS feeds
Review ArticleTeaching Case Studies

False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine

Joseph A. Frankl, Sudeshna Bose and Phillip H. Kuo
Journal of Nuclear Medicine Technology June 2018, 46 (2) 149-150; DOI: https://doi.org/10.2967/jnmt.117.201558
Joseph A. Frankl
1College of Medicine, University of Arizona, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sudeshna Bose
2Department of Neurology, University of Arizona, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Phillip H. Kuo
3Department of Medical Imaging, University of Arizona, Tucson, Arizona;
4Departments of Medicine and Biomedical Engineering, University of Arizona, Tucson, Arizona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Dopamine transporter SPECT is an accurate adjunct to clinical evaluation for Parkinson disease when the diagnosis is difficult. Dopaminergic medications may significantly affect dopamine transporter availability and, thus, uptake of dopamine transporter tracers. A patient had a false-positive dopamine transporter SPECT result while she was taking dextroamphetamine and amphetamine for attention-deficit hyperactivity disorder. The SPECT findings normalized after amphetamine therapy was withheld. An accurate medication history combined with knowledge of drugs that interfere with dopamine transporter imaging is critical to ensure accuracy.

  • dopamine transporter
  • single-photon positron emission tomography
  • ioflupane
  • Parkinson disease
  • amphetamine

Dopamine transporter localization with 123I-ioflupane and SPECT is an accurate and well-established test to differentiate Parkinson disease from similar clinical entities not associated with presynaptic neuronal dysfunction (1). However, the images can be degraded by positioning artifacts and dopaminergic drugs (1–3). We present a case in which dopamine transporter SPECT showed findings that were suggestive of Parkinson disease while the patient was taking dextroamphetamine and amphetamine for attention-deficit hyperactivity disorder and then were normal after amphetamines were withheld. Institutional review board approval was not required for this case report.

CASE REPORT

A 60-y-old woman with bipolar disorder treated with valproate and ziprasidone, and attention-deficit hyperactivity disorder treated with dextroamphetamine and amphetamine (15 mg/d), presented with a 2-mo history of progressive tremors and instability. The patient’s neurologist started her on carbidopa and levodopa and ordered a dopamine transporter SPECT scan, and her psychiatrist decreased her valproate dosage. The scan, obtained while the patient was taking dextroamphetamine and amphetamine, were interpreted as showing reduced activity in the left putamen, consistent with Parkinson disease (Fig. 1).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

(A) Decreased activity in left putamen (arrows) on dopamine transporter SPECT images obtained while patient was receiving dextroamphetamine and amphetamine supports diagnosis of Parkinson disease. (B) Typical normal dopamine transporter SPECT findings using same camera and reconstruction protocol.

Although the patient’s symptoms had improved 1 mo after the change in medication, significant residual symptoms remained. Discontinuation of the ziprasidone led to further improvement. Because the symptoms were not responding as would be expected for typical Parkinson disease, and especially because the results of the dopamine transporter imaging were only mildly abnormal, the neurologist and the nuclear medicine physician together reviewed the patient’s chart for potentially interfering medications. The physicians agreed to repeat the imaging after the dextroamphetamine and amphetamine had been withheld for 7 wk, and the results were normal (Fig. 2). Therefore, drug-induced parkinsonism was considered most likely.

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Dopamine transporter SPECT images obtained on different camera showed normalization after 7 wk without dextroamphetamine and amphetamine.

DISCUSSION

The patient’s initial dopamine transporter SPECT study, obtained while she was taking amphetamines for attention-deficit hyperactivity disorder, was positive for Parkinson disease, but the repeated study, obtained after amphetamines had been withheld for 7 wk, was negative for Parkinson disease. This case demonstrates that therapeutic doses of amphetamines can significantly alter dopamine transporter imaging. Our findings are consistent with animal models showing that methylphenidate—which, like dextroamphetamine and amphetamine, reduces dopamine transporter availability—decreases the dopamine transporter SPECT signal (4).

For patients taking amphetamines, a 1-wk washout period has been recommended before dopamine transporter SPECT (1). However, even after 2 wk of abstinence, recreational users of dextroamphetamine have been shown to have a lower striatal SPECT signal than healthy controls (5). Although one case is not sufficient to determine an optimal washout period, 7 wk was used here for normalization of dopamine transporter imaging.

CONCLUSION

An accurate medical history and knowledge of medications that interfere with dopamine transporter imaging are critical to ensure that drugs are properly withheld beforehand.

DISCLOSURE

Phillip H. Kuo has consulted for and received grants from GE Healthcare. No other potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Dec. 22, 2017.

REFERENCES

  1. 1.↵
    1. Kägi G,
    2. Bhatia KP,
    3. Tolosa E
    . The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010;81:5–12.
    OpenUrlAbstract/FREE Full Text
  2. 2.
    1. Covington MF,
    2. McMillan NA,
    3. Avery RJ,
    4. Kuo PH
    . The semicolon sign: dopamine transporter imaging artifact from head tilt. J Nucl Med Technol. 2013;41:105–107.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Janicek AK,
    2. Avery RJ,
    3. Kuo PH
    . The pinwheel sign: artifact from head rotation during SPECT acquisition for dopamine transporter imaging. J Nucl Med Technol. 2014;42:75–76.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Nikolaus S,
    2. Wirrwar A,
    3. Antke C,
    4. et al
    . Quantitation of dopamine transporter blockade by methylphenidate: first in vivo investigation using [123I]FP-CIT and a dedicated small animal SPECT. Eur J Nucl Med Mol Imaging. 2005;32:308–313.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Schouw MLJ,
    2. Caan MWA,
    3. Geurts HM,
    4. et al
    . Monoaminergic dysfunction in recreational users of dexamphetamine. Eur Neuropsychopharmacol. 2013;23:1491–1502.
    OpenUrl
  • Received for publication August 31, 2017.
  • Accepted for publication October 30, 2017.
View Abstract
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine Technology: 46 (2)
Journal of Nuclear Medicine Technology
Vol. 46, Issue 2
June 1, 2018
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine Technology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine
(Your Name) has sent you a message from Journal of Nuclear Medicine Technology
(Your Name) thought you would like to see the Journal of Nuclear Medicine Technology web site.
Citation Tools
False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine
Joseph A. Frankl, Sudeshna Bose, Phillip H. Kuo
Journal of Nuclear Medicine Technology Jun 2018, 46 (2) 149-150; DOI: 10.2967/jnmt.117.201558

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
False-Positive Findings on Dopamine Transporter SPECT Due to Therapeutic Dextroamphetamine and Amphetamine
Joseph A. Frankl, Sudeshna Bose, Phillip H. Kuo
Journal of Nuclear Medicine Technology Jun 2018, 46 (2) 149-150; DOI: 10.2967/jnmt.117.201558
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • CASE REPORT
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • A Quick Guide to Writing a Teaching Case Study
  • Google Scholar

More in this TOC Section

  • High-Sensitivity Troponin Elevation in a Young Woman with Typical Chest Pain: The Heart of the Matter
  • Pulmonary Adenocarcinoma Revealed by Parathyroid Scintigraphy: An Incidental Case to Remember
  • Prominent Right Ventricular Tracer Uptake: A Harbinger of Multivessel Coronary Artery Disease
Show more Teaching Case Studies

Similar Articles

Keywords

  • dopamine transporter
  • single-photon positron emission tomography
  • ioflupane
  • Parkinson disease
  • amphetamine
SNMMI

© 2025 SNMMI

Powered by HighWire